No approval for Sputnik V vaccine yet; Drug authority seeks additional data from Dr Reddy’s

An expert panel of India’s central drug authority has sought additional data and information from Dr Reddy’s Laboratories, which has sought emergency use authorisation for Russian Covid-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-Covid-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

“It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points. It has also asked the drug-maker to submit the factsheet,” a source said.

“We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback,” Dr Reddy’s Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.

  • Related Posts

    Police bust illegal medicine supply racket

    New Delhi: Delhi Police’s crime branch has busted an illegal medicine supply racket in west Delhi and arrested a 47-year-old owner of a medical store who was allegedly selling restricted…

    2 medical store owners held in drug supply racket in Delhi

    Official said 3,360 Tramadol capsules, weighing around two kilogrammes, and 84 bottles of Codeine Phosphate Syrup of 100 millilitre each were seized in September last year. The anti-narcotics task force…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Police bust illegal medicine supply racket

    Police bust illegal medicine supply racket

    2 medical store owners held in drug supply racket in Delhi

    2 medical store owners held in drug supply racket in Delhi

    Maharashtra FDA appoints 34 lab personnel for its Mumbai based drug testing lab

    Maharashtra FDA appoints 34 lab personnel for its Mumbai based drug testing lab

    Ayush export declines by 7.4% in first nine months of FY 26

    Ayush export declines by 7.4% in first nine months of FY 26

    Three State Drug Testing Laboratories Functional in Jammu Kashmir: GoI

    Three State Drug Testing Laboratories Functional in Jammu Kashmir: GoI

    One more illegal drug manufacturing factory busted in Gaya, 9th Kingpin Nabbed amid Massive Seizure

    One more illegal drug manufacturing factory busted in Gaya, 9th Kingpin Nabbed amid Massive Seizure